Northwest Biotherapeutics (NBYB) Income Statement
Northwest Biotherapeutics Income Statement
Last quarter (Q2 2026), Northwest Biotherapeutics's total revenue was $807.00K, an increase of 516.03% from the same quarter last year. In Q2, Northwest Biotherapeutics's net income was $-9.22M. See Northwest Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 1.38M | $ 1.38M | $ 1.93M | $ 1.68M | $ 1.00M | |
| $ -959.00K | $ 1.38M | $ -25.80M | $ 135.00K | $ -19.30M | |
| $ 58.95M | $ 67.89M | $ 57.44M | $ 68.86M | $ 53.71M | |
| Depreciation and Amortization | $ 2.34M | $ 2.04M | $ 1.73M | $ 1.50M | $ 586.00K |
| $ -49.67M | $ -73.64M | $ -55.34M | $ -97.46M | $ 184.72M | |
| $ -59.91M | $ -66.51M | $ -55.51M | $ -67.18M | $ -52.70M | |
| $ -785.00K | $ -17.27M | $ -7.09M | $ -37.85M | $ 231.83M | |
| $ -60.70M | $ -83.78M | $ -62.60M | $ -105.03M | $ 179.13M | |
| $ -61.48M | $ -83.78M | $ -62.60M | $ -105.03M | $ 179.13M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.04 | $ -0.07 | $ -0.06 | $ -0.10 | $ 0.21 |
| Diluted EPS | $ -0.04 | $ -0.07 | $ -0.06 | $ -0.10 | $ -0.06 |
| Weighted Average Shares Outstanding | 1.46B | 1.24B | 1.12B | 1.02B | 873.52M |
| Weighted Average Shares Outstanding (Diluted) | 1.46B | 1.24B | 1.12B | 1.02B | 1.01B |
Currency in USD
